Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 2.0300 |
| Open | 2.0200 |
| Bid | 1.9100 x 1300 |
| Ask | 2.2000 x 1000 |
| Day's range | 2.0000 - 2.1400 |
| 52-week range | 1.2500 - 8.5900 |
| Volume | |
| Avg. volume | 149,788 |
| Market cap | 47.12M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
SAN FRANCISCO, August 10, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates.
- Business Wire
Spruce Biosciences to Participate in June Investor Conferences
SAN FRANCISCO, June 01, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in June.
- Business Wire
Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference
SAN FRANCISCO, May 31, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, GA. In a recorded presentation, the company will highlight results from a recent
